ClinicalTrials.gg
Active, not recruitingNCT02822378Updated Jul 6, 2026

Dried Plums and Bone Health in Postmenopausal Women

An interventional study of Dried Plum and Calcium supplement in Postmenopausal Osteoporosis, sponsored by Penn State University. Active, not recruiting at 1 site in United States. Open to female participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Penn State University · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
322
Allocation
Randomized
Ages
55 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Osteoporosis, Postmenopausal with a site in United States — 4 open to participants now, 11 under way, 1 of them phase 3. Osteoporosis, Postmenopausal · United States.

Enrollment
35th of 95
322 · median 201
Started
2016
with 2 others
No phase
16 of 106
2 open now
Primary completion
2027-12
later than 7 of 10 live
Registered
73rd of 106
by date

Among the 106 studies in Osteoporosis, Postmenopausal with a site in United States, this one is the 35th largest by enrollment of the 95 interventional ones that give a count, is one of 3 that started in 2016, is one of 16 with no phase, reaches primary completion later than 7 of the 10 other live ones, and was the 73rd registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

4 of the 106 studies in Osteoporosis, Postmenopausal with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Osteoporosis, Postmenopausal with a site in United States, or all of them as a file.
02

Study summary

Postmenopausal women often seek non-pharmacologic interventions for the protection of bone health. Previous research in humans and rodents has indicated that dietary dried plum consumption may be beneficial for bone health, especially in postmenopausal women. However, it is unknown in what quantity dried plums need to be consumed to be of benefit and through what mechanisms dried plums act to impact bone health. Therefore, the purpose of this study is to evaluate the impact of 52 weeks of dried plums consumption in varying quantities on bone mineral density (BMD), bone geometry, and estimated bone strength in postmenopausal women. The investigators also seek to evaluate the mechanisms underlying the effects of dried plums as a dietary supplement by assessing polyphenols and the bioavailable conjugated metabolites in the urine of postmenopausal women taking different doses of dietary dried plums. The investigators aim to further investigate the mechanisms of dried plum action on bone by measuring markers of bone metabolism in response to dried plum consumption.

Read the detailed description

Given the current high incidence of osteoporosis, reducing the risk of osteoporosis development is essential. Recent estimates, based on the 2010 US Census, indicate that approximately 10.3 million people age 50 and older have osteoporosis. By 2030 the prevalence of osteoporosis for women 50 years and older is projected to reach 13.6 million. Postmenopausal osteoporosis is characterized not only by hypoestrogenism, but also by increased production of reactive oxygen species, oxidative stress, and inflammatory response. Current first line strategies are treatment of osteoporosis with pharmacologic approaches. Complementary recommendations include the maintenance of calcium (Ca2+) and vitamin D (VitD) intake to meet the current recommendations. Although the anti-resorptive therapies are effective they are also associated with an array of negative side effects, which reduce patient compliance to use of the therapy.

Non-pharmacologic options to reducing the risk of bone loss are becoming more attractive to many postmenopausal women. The phenolics and bioavailable conjugated metabolites found in dried plums are proposed to modulate the inflammatory signaling pathways and have the potential to influence bone formation and bone resorption, thus modulating the risk of bone loss. The investigators are conducting a 52 week dose ranging randomized controlled trial that builds upon previous rodent and human work and addresses the experimental design limitations of the previous work, to assess bone outcomes with clinical (BMD) and mechanistic (bone geometry, bone metabolism markers, and inflammation markers) techniques. Additionally, this study will include a detailed assessment of the phenolics in the dried plums to explore the relationship between these compounds and bone outcomes.

Participants will participate in a 1-2 week screening period followed by a 1-2 week baseline period. At the end of baseline randomization to 1 of 3 groups will occur (Ca2+ and VitD only; 50g Dried Plums/day and Ca2+ and VitD; 100g Dried Plums/day and Ca2+ and VitD). Dried plums and Calcium/Vitamin D supplements will be provided to participants for the duration of the intervention. At the beginning of the 52 week intervention participants will begin consumption of dried plums and will be given a run in period where the number of dried plums consumed per day increases slowly to minimize the side effects felt by the participants. The dried plums will be consumed as snacks in the morning, midday, and in the evening. Participants will visit the laboratory for testing every 4 weeks during the 52 week intervention, with more testing occurring during weeks 12, 24, 36, and 52 than the other testing periods.

At testing period visits participants will be asked to complete some or all of the following: body weight measurement; blood sampling; 24-hour urine collection; stool sample collection; DXA scan; peripheral quantitative computed tomography (pQCT) scan; completion of health, physical activity, and nutrition questionnaires; completion of supplement/symptom, diet, and physical activity logs.

A total of 300 participants will be enrolled and screed with an expected randomization of 79 participants per group. The investigators anticipate a 20% drop-out rate between baseline and week 52, thus will anticipate having a final sample size of 63 participants per group complete the study. This sample size provides over 80% power to detect differences with the primary BMD, bone geometry, and bone strength variables.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • Postmenopausal Osteoporosis
  • Human
  • Female
  • Non-pharmacologic therapy
04

Who can participate

Ages eligible
55 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women
  • not severely obese ( \< 40 kg/m2);
  • healthy (determined by a screening questionnaire, complete metabolic panel);
  • willing to include dried plums in their daily diet;
  • not taking any natural dietary supplement containing phenolics, blueberries or apples for at least 2 months prior to study entry; can stop for 2 months to meet entry criteria
  • non-smoking; ambulatory;
  • low BMD as measured by dual energy X-ray absorptiometry (DXA). Eligible BMD values (T-scores) for DXA measures of the lumbar spine, total hip and/or femoral neck will correspond to T-scores between 0 and -3.0.

Exclusion criteria

Exclusion Criteria:

  • Women who regularly consume dried plums, dried apples, prune juice, or heavy consumers of blueberries (1 cup or more/day). Potential volunteers who will refrain from consumption of the afore mentioned foods for the duration of the study will become eligible after a 2 month ;
  • vitamin D deficiency (\<20 ng/mL);
  • history of vertebral fracture or fragility fracture of the wrist, humerus, hip or pelvis after age 50 yr);
  • untreated hyper- or hypothyroidism;
  • current hyper- or hypoparathyroidism;
  • significantly impaired renal function; high potassium
  • current hypo- or hypercalcemia;
  • history of spinal stenosis;
  • history of heart attack, stroke, thromboembolism, kidney disease, malabsorption syndrome, seizure disorders;
  • positive for , Hep-C or Hep-B surface antigen and .
  • Use of the following agents affecting bone metabolism:

    • intravenous bisphosphonates at any time;
    • fluoride (for osteoporosis) within the past 24 months;
    • denosumab at any time;
    • bisphosphonates, parathyroid hormone or strontium within the past 12 months;
    • calcitonin or selective estrogen receptor modulators within the past 12 months;
    • systemic oral or transdermal estrogen within the past 3 months;
    • systemic glucocorticosteroids (≥ 5 mg prednisone equivalent per day for more than 10 days); or
    • tibolone within the past 3 months.
  • Participants who will not consume study therapy or will not stop taking natural product supplements of their own selection.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
322 participants (actual)

Study arms

  • Experimental
    Ca2+/VitD Control

    Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Participants will be asked to refrain from consumption of dried plums for the duration of the intervention (52 weeks).

    Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D supplement

  • Experimental
    50g Dried Plums

    Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 6 (50g) dried plums per day for the duration of the intervention (52 weeks).

    Dietary Supplement: Dried Plum · Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D supplement

  • Experimental
    100g Dried Plums

    Participants will take calcium and vitamin D supplements for the duration of the baseline and intervention. Additionally, participants will be provided with dried plums and asked to consume 12 (100g) dried plums per day for the duration of the intervention (52 weeks).

    Dietary Supplement: Dried Plum · Dietary Supplement: Calcium supplement · Dietary Supplement: Vitamin D supplement

Interventions

  • Dietary supplementPruneStudies of PrunePrune pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.

    Also known as: Prunes

  • Dietary supplementCalcium supplement

    All participants will consume calcium supplements for the duration of baseline and intervention.

  • Dietary supplementVitamin DStudies of Vitamin DVitamin D pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All participants will consume vitamin D supplements for the duration of baseline and intervention.

06

What researchers measure

Primary outcomes

  1. Percent change from baseline in areal bone mineral density (via DXA) of the lumbar spine, total hip, and femoral neck

    Percent change in areal BMD measured during screening, and weeks 24 and 52 of the 52 week dietary intervention at the lumbar spine, total hip, and femoral neck.

    Time frame: at screening, week 24, and week 52

Secondary outcomes

  1. Percent change from baseline in DXA hip structural analysis

    Percent change in hip structural analysis (HSA) measured during screening, and weeks 24 and 52 of the 52 week dietary intervention at the total hip.

    Time frame: at screening, week 24, and week 52

  2. Percent change from baseline in DXA spine trabecular bone score

    Percent change in trabecular bone score (TBS) measured during screening, and weeks 24 and 52 of the 52 week dietary intervention at the lumbar spine.

    Time frame: at screening, week 24, and week 52

  3. Percent change from baseline in pQCT volumetric BMD of the tibia and radius

    Percent change in volumetric BMD, cortical and trabecular compartments, measured during baseline, and weeks 24 and 52 of the 52 week dietary intervention at the tibia and radius. The combination of measurements will provide an overall picture of the 3-dimensional structure of a weight bearing (tibia) and non-weight bearing (radius) site and how the sites are impacted by the intervention.

    Time frame: at baseline, week 24, and week 52

  4. Percent change from baseline in pQCT geometry measurements of the tibia and radius

    Percent change in bone geometry estimates measured during baseline, and weeks 24 and 52 of the 52 week dietary intervention at the tibia and radius. The combination of measurements will provide an overall picture of the 3-dimensional structure of a weight bearing (tibia) and non-weight bearing (radius) site and how the sites are impacted by the intervention.

    Time frame: at baseline, week 24, and week 52

  5. Percent change from baseline in pQCT strength measurements of the tibia and radius

    Percent change in bone strength estimates measured during baseline, and weeks 24 and 52 of the 52 week dietary intervention at the tibia and radius. The combination of measurements will provide an overall picture of the 3-dimensional structure of a weight bearing (tibia) and non-weight bearing (radius) site and how the sites are impacted by the intervention.

    Time frame: at baseline, week 24, and week 52

  6. Change from baseline in bone turnover markers

    Change in serially-sampled fasting serum concentrations of bone formation (N-terminal type 1 procollagen; P1NP) and bone resorption (crosslaps; CTx) before, during and after the dietary intervention. The combined measures will provide information regarding changes in the rate of bone resorption and bone formation.

    Time frame: at baseline, week 12, week 24, week 36, and week 52

Other outcomes

  1. Change from baseline in cellular bone metabolism

    Change in serially-sampled fasting serum concentrations of bone signaling markers (i.e., Insulin like growth factor-1 \[IGF-1\], osteoprotegerin \[OPG\], receptor activator of nuclear factor kappaB ligand \[RANKL\], and sclerostin \[SOST\]) before, during and after the dietary intervention. Changes in these variables will assist in understanding the underlying mechanisms behind changes in the rates of bone resorption and bone formation.

    Time frame: at baseline, week 12, week 24, week 36, and week 52

  2. Change from baseline in urine phenolic concentrations

    Change in serially-sampled 24 hour urine concentrations of phenolic compounds attributable to dried plum consumption.

    Time frame: at baseline and every 4 weeks during the intervention

  3. Change from baseline in serum phenolic concentrations

    Change in serially-sampled fasting serum concentrations of phenolic compounds attributable to dried plum consumption.

    Time frame: at baseline, week 12, week 24, week 36, and week 52

  4. Change from baseline in expression of inflammatory markers

    Change in peripheral blood mononuclear cell (PBMC) gene expression of inflammatory markers before, during and after the dietary intervention. Additionally, the relationship between the changes in gene expression of inflammation markers and bone outcomes will be explored. The combined changes of the gene expression of inflammatory markers will provide a comprehensive picture of the inflammatory environment of the participants before, during and following the dietary intervention. This comprehensive picture will assist in understanding the mechanisms by which the inflammatory environment contributes to bone loss in postmenopausal women and how the dietary intervention impacts these factors.

    Time frame: at baseline, week 12, week 24, week 36, and week 52

  5. Change from baseline in gut microbiome

    Serially-sampled stool samples for assessment of changes in the gut microbiome before, during and after the dietary intervention. Additionally, the relationship between the changes in the gut microbiome and bone outcomes will be explored.

    Time frame: at baseline, week 24, and week 52

07

Study locations

1 site
08

References and documents

Publications

  • Damani JJ, Rogers CJ, Lee H, Strock NC, Koltun KJ, Williams NI, Weaver C, Ferruzzi MG, Nakatsu CH, De Souza MJ. Effects of Prune (Dried Plum) Supplementation on Cardiometabolic Health in Postmenopausal Women: An Ancillary Analysis of a 12-Month Randomized Controlled Trial, The Prune Study. J Nutr. 2024 May;154(5):1604-1618. doi: 10.1016/j.tjnut.2024.03.012. Epub 2024 Mar 13. PubMed 38490532 ↗
  • Damani JJ, Oh ES, De Souza MJ, Strock NC, Williams NI, Nakatsu CH, Lee H, Weaver C, Rogers CJ. Prune Consumption Attenuates Proinflammatory Cytokine Secretion and Alters Monocyte Activation in Postmenopausal Women: Secondary Outcome Analysis of a 12-Mo Randomized Controlled Trial: The Prune Study. J Nutr. 2024 May;154(5):1699-1710. doi: 10.1016/j.tjnut.2023.11.014. Epub 2023 Nov 19. PubMed 37984741 ↗
  • De Souza MJ, Strock NCA, Williams NI, Lee H, Koltun KJ, Rogers C, Ferruzzi MG, Nakatsu CH, Weaver C. Prunes preserve hip bone mineral density in a 12-month randomized controlled trial in postmenopausal women: the Prune Study. Am J Clin Nutr. 2022 Oct 6;116(4):897-910. doi: 10.1093/ajcn/nqac189. PubMed 35798020 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2016 (actual). Primary completion is estimated for Dec 2027, 138 months after the start.

Of 48 non-industry interventional studies with no phase under Osteoporosis, Postmenopausal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 34. This study's planned 138 months is above that.

Counting every sponsor, half of 51 studies reached it within 17 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2016
First posted
Jul 4, 2016
StartActual
Jun 1, 2016
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02822378
Collaborators
California Dried Plum Board
Responsible party
Mary Jane DeSouza (Professor of Kinesiology and Physiology, Penn State University) — Principal investigator
First posted
Jul 4, 2016
Start date
Jun 1, 2016
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Mary Jane De Souza, PhD
principal investigator · The Pennsylvania State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prune

Start the discussion